Methods for diagnosing Noonan syndrome
View Patent ↗Diagnostic and therapeutic applications for Noonan Syndrome are described. The diagnostic and therapeutic applications are based on certain mutations in the protein tyrosine phosphatase gene PTPN11 and its expression product, PTPN11, as well as mutations in other components in a PTPN11 signal transduction pathway promoting an increased signaling flux. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to PTPN11 and PTPN11 variants, and cells expressing such variants.
1. A method for diagnosing Noonan syndrome in a human subject, said method comprising the step of detecting a mutation in a protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule of SEQ ID NO: 1 from said subject, wherein said mutation results in an amino acid substitution in a PTPN11 protein tyrosine phosphatase (PTP) domain, and wherein said amino acid substitution is selected from the group consisting of:
(a) a Y to C substitution at position 279 of SEQ ID NO: 2;
(b) an I to V substitution at position 282 of SEQ ID NO:2;
(c) an F to L substitution at position 285 of SEQ ID NO:2;
(d) an F to S substitution at position 285 of SEQ ID NO:2;
(e) an N to D substitution at position 308 of SEQ ID NO:2;
(f) an N to S substitution at position 308 of SEQ ID NO:2;
(g) an I to V substitution at position 309 of SEQ ID NO:2;
(h) an R to K substitution at position 501 of SEQ ID NO:2; and
(i) an M to V substitution at position 504 of SEQ ID NO:2,
wherein the presence of said mutation in said protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.
2. A method for diagnosing Noonan syndrome in a human subject, said method comprising the step of detecting a mutation in a protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule of SEQ ID NO: 1 from said subject, wherein said mutation results in an amino acid substitution in a PTPN11 protein tyrosine phosphatase (PTP) domain, and wherein said mutation in the PTPN11 nucleic acid molecule is selected from the group consisting of:
(a) an A to G substitution at position 836 of SEQ ID NO:1;
(b) an A to G substitution at position 844 of SEQ ID NO:1;
(c) a T to C substitution at position 853 of SEQ ID NO:1;
(d) a T to C substitution at position 854 of SEQ ID NO:1;
(e) an A to G substitution at position 922 of SEQ ID NO:1;
(f) an A to G substitution at position 923 of SEQ ID NO:1;
(g) an A to G substitution at position 925 of SEQ ID NO:1;
(h) a G to A substitution at position 1502 of SEQ ID NO:1;
(i) an A to G substitution at position 1510 of SEQ ID NO:1,
wherein the presence of said mutation in said protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.
3. A method for diagnosing Noonan syndrome in a human subject, said method comprising the step of detecting a mutation in a protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule of SEQ ID NO: 1 from said subject, wherein said mutation results in an amino acid substitution in a PTPN11 src homology-2 (SH2) domain, and wherein said amino acid substitution is selected from the group consisting of:
(a) a G to A substitution at position 60 of SEQ ID NO:2;
(b) a D to N substitution at position 61 of SEQ ID NO:2;
(c) a D to G substitution at position 61 of SEQ ID NO:2;
(d) a Y to D substitution at position 62 of SEQ ID NO:2;
(e) a Y to C substitution at position 63 of SEQ ID NO:2;
(f) an A to S substitution at position 72 of SEQ ID NO:2;
(g) an A to G substitution at position 72 of SEQ ID NO:2;
(h) an E to D substitution at position 76 of SEQ ID NO:2; and
(i) a Q to R substitution at position 79 of SEQ ID NO:2;
wherein the presence of said mutation in said protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.
4. A method for diagnosing Noonan syndrome in a human subject, said method comprising the step of detecting two or more mutations in a protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule of SEQ ID NO: 1 from said subject, wherein said mutation results in an amino acid substitution and a deletion in a PTPN11 src homology-2 (SH2) domain, and wherein said mutations results in a G to V amino acid substitution at position 60 and a deletion of amino acid D at position 61 of SEQ ID NO:2, wherein the presence of said two or more mutations in said protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.
5. A method for diagnosing Noonan syndrome in a human subject, said method comprising the step of detecting a mutation in a protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule of SEQ ID NO: 1 from said subject, wherein said mutation results in an amino acid substitution in a PTPN11 src homology-2 (SH2) domain, and wherein said mutation in the PTPN11 nucleic acid molecule is selected from the group consisting of:
(a) a G to C substitution at position 179 of SEQ ID NO:1;
(c) a G to A substitution at position 181 of SEQ ID NO:1;
(d) an A to G substitution at position 182 of SEQ ID NO:1;
(e) a T to G substitution at position 184 of SEQ ID NO:1;
(f) an A to G substitution at position 188 of SEQ ID NO:1;
(g) a G to T substitution at position 214 of SEQ ID NO:1;
(h) a C to G substitution at position 215 of SEQ ID NO:1;
(j) an G to C substitution at position 228 of SEQ ID NO:1;
(k) an A to G substitution at position 236 of SEQ ID NO:1; and
wherein the presence of said mutation in said protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.
6. A method for diagnosing Noonan syndrome in a human subject, said method comprising the step of detecting two or more mutations in a protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule of SEQ ID NO: 1 from said subject, wherein said mutation results in an amino acid substitution and a deletion in a PTPN11 src homology-2 (SH2) domain, and wherein said mutations in the PTPN11 nucleic acid molecule include a G to T substitution at position 179 and a deletion of positions 180-182 of SEQ ID NO:1, wherein the presence of said two or more mutations in said protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.
7. A method for diagnosing Noonan syndrome in a human subject, said method comprising the step of detecting a mutation in a protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule of SEQ ID NO: 1 from said subject, wherein said mutation results in an amino acid substitution in a PTPN11 protein linker domain connecting a first SH2 domain to a second SH2 domain, and wherein said amino acid substitution is a D to A amino acid substitution at position 106 of SEQ ID NO:2, wherein the presence of said mutation in said protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.
8. A method for diagnosing Noonan syndrome in a human subject, said method comprising the step of detecting a mutation in a protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule of SEQ ID NO: 1 from said subject, wherein said mutation results in an amino acid substitution in a PTPN11 protein linker domain connecting a first SH2 domain to a second SH2 domain, and wherein said mutation in the PTPN11 nucleic acid molecule is an A to C substitution at position 317 of SEQ ID NO:1, wherein the presence of said mutation in said protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.
9. A method for diagnosing Noonan syndrome in a human subject, said method comprising the step of detecting a mutation in a protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule of SEQ ID NO: 1 from said subject, wherein said mutation results in an amino acid substitution in a PTPN 11 protein tyrosine phosphatase (PTP) domain, and wherein said amino acid substitution is selected from the group consisting of:
(a) a G to S substitution at position 268 of SEQ ID NO:2;
(b) an N to T substitution at position 308 of SEQ ID NO:2;
(c) an P to S substitution at position 491 of SEQ ID NO:2; and
(d) an S to L substitution at position 502 of SEQ ID NO:2,
wherein the presence of said mutation in said protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.
10. A method for diagnosing Noonan syndrome in a human subject, said method comprising the step of detecting a mutation in a protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule of SEQ ID NO: 1 from said subject, wherein said mutation results in an amino acid substitution in a PTPN11 protein tyrosine phosphatase (PTP) domain, and wherein said mutation in the PTPN11 nucleic acid molecule is selected from the group consisting of:
(a) a G to A substitution at position 802 of SEQ ID NO:1;
(b) an A to C substitution at position 923 of SEQ ID NO:1;
(c) a C to T substitution at position 1471 of SEQ ID NO:1; and
(d) a C to T substitution at position 1505 of SEQ ID NO:1,
wherein the presence of said mutation in said protein tyrosine phosphatase 11 (PTPN11) nucleic acid molecule is diagnostic of Noonan syndrome in said human subject.